244 related articles for article (PubMed ID: 15024437)
1. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance.
Low DE; Pichichero ME; Schaad UB
Clin Pediatr (Phila); 2004 Mar; 43(2):135-51. PubMed ID: 15024437
[TBL] [Abstract][Full Text] [Related]
2. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of antibacterial resistance in community-acquired respiratory tract infections in children.
Cunha BA
Infection; 2004 Apr; 32(2):98-108. PubMed ID: 15057574
[TBL] [Abstract][Full Text] [Related]
4. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
5. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
Sunakawa K; Farrell DJ
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
[TBL] [Abstract][Full Text] [Related]
7. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
8. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
Felmingham D; Zhanel G; Hoban D
J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
[TBL] [Abstract][Full Text] [Related]
9. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
Sakata H
Jpn J Antibiot; 2001 May; 54 Suppl B():96. PubMed ID: 12638154
[No Abstract] [Full Text] [Related]
11. Clinical efficacy of new antibacterial therapies in at-risk populations.
Lorenz J
J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological features and chemotherapy of community-acquired respiratory tract infections.
Finch RG
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():53-61. PubMed ID: 2292531
[TBL] [Abstract][Full Text] [Related]
13. [Antibiotics in bacterial acute respiratory tract infection in children].
Tatochenko VK; Katosova LK
Antibiot Khimioter; 1999; 44(9):13-8. PubMed ID: 10511903
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
[TBL] [Abstract][Full Text] [Related]
17. New developments in antibacterial choice for lower respiratory tract infections in elderly patients.
Ferrara AM; Fietta AM
Drugs Aging; 2004; 21(3):167-86. PubMed ID: 14979735
[TBL] [Abstract][Full Text] [Related]
18. Elderly patients with community-acquired pneumonia: optimal treatment strategies.
Thiem U; Heppner HJ; Pientka L
Drugs Aging; 2011 Jul; 28(7):519-37. PubMed ID: 21721597
[TBL] [Abstract][Full Text] [Related]
19. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
20. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
Barberán J; Mensa J
Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
